Back to All Events

Keratoconus: Overview and Current Treatments

 
 

CXL has been approved in the U.S. for nearly a decade now. Dr. Lee will share the most memorable clinical lessons on CXL that has shaped his own clinical practice today, including the significance of FDA-approved CXL, how has it impacted patient quality-of-life (QoL) and reshaped clinical management, how to determine progression for treatment, can older patients progress, can patient younger than 14 be treated and his personal experience of retreating patients who continued to progress after investigational CXL treatments.

Speaker: Dr. Barry Lee

Date: Tuesday, August 5, 2025

Time: 5:30 PM - 6:30 PM Pacific Time

Location: Virtual

Moderator: Dr. Ariel Cerenzie

Cost: Free!

COPE ID: 98767-TD

Category: Trt/Mngmnt Ocular Disease

This event is undergoing COPE approval for 1 hour of CE credit.

Thank you to Glaukos for providing an educational grant for this event.

Previous
Previous
August 4

Corneal Hysteresis and IOPcc: Glaucoma Vitals for the Modern Era

Next
Next
August 6

In the Blink of An Eye: How Blinking Mechanics Impact Dry Eye Disease